Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial.
Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial.
复制标题
DOI：
10.2196/20904
复制
发表时间：
2020-11-19
影响因子：
1.7
通讯作者：
D'Alessandro U
中科院分区：
文献类型：
--
作者：
Dabira ED;Soumare HM;Lindsay SW;Conteh B;Ceesay F;Bradley J;Kositz C;Broekhuizen H;Kandeh B;Fehr AE;Nieto-Sanchez C;Ribera JM;Peeters Grietens K;Smit MR;Drakeley C;Bousema T;Achan J;D'Alessandro U
随着疟疾负担的下降，需要创新的干预措施和工具来进一步减少疟疾传播。在病媒控制干预措施覆盖率已经很高的地方，以青蒿素为基础的联合疗法的大规模给药已被确定为进一步减少疟疾传播的潜在工具。然而，这种影响是有限的。将青蒿素联合青蒿素与能够减少病媒存活的杀灭内灭剂治疗（如伊维菌素）相结合，可以增加丙二醛的影响，并提供减少疟疾传播的新工具。该研究的目的是评估在疟疾控制干预措施覆盖率高的地区，用IVM联合双氢青蒿素-哌喹（DP）对疟疾传播的影响。该研究是在冈比亚上游河流地区进行的一项集群随机试验，包括32个村庄（16个对照和16个干预）。在所有干预集群周围建立了约2公里的缓冲区。在所有干预村和缓冲区实施了综合防治和综合规划方案；对照村根据冈比亚国家疟疾控制规划计划接受了标准的疟疾干预措施。MDA活动第一年于2018年8月至10月进行，第二年于2019年7月至9月进行。一旦数据库完成、清理和锁定，统计分析将开始。这是MDA联合IVM + DP的首个集群随机临床试验。该结果将提供证据，证明丙二醛联合IVM加DP对疟疾传播的影响。ClinicalTrials.gov NCT03576313;https://clinicaltrials.gov/ct2/show/NCT03576313 derr1 - 10.2196/20904
With a decline in malaria burden, innovative interventions and tools are required to reduce malaria transmission further. Mass drug administration (MDA) of artemisinin-based combination therapy (ACT) has been identified as a potential tool to further reduce malaria transmission, where coverage of vector control interventions is already high. However, the impact is limited in time. Combining an ACT with an endectocide treatment that is able to reduce vector survival, such as ivermectin (IVM), could increase the impact of MDA and offer a new tool to reduce malaria transmission. The study objective is to evaluate the impact of MDA with IVM plus dihydroartemisinin-piperaquine (DP) on malaria transmission in an area with high coverage of malaria control interventions. The study is a cluster randomized trial in the Upper River Region of The Gambia and included 32 villages (16 control and 16 intervention). A buffer zone of ~2 km was created around all intervention clusters. MDA with IVM plus DP was implemented in all intervention villages and the buffer zones; control villages received standard malaria interventions according to the Gambian National Malaria Control Program plans. The MDA campaigns were carried out from August to October 2018 for the first year and from July to September 2019 for the second year. Statistical analysis will commence once the database is completed, cleaned, and locked. This is the first cluster randomized clinical trial of MDA with IVM plus DP. The results will provide evidence on the impact of MDA with IVM plus DP on malaria transmission. ClinicalTrials.gov NCT03576313; https://clinicaltrials.gov/ct2/show/NCT03576313 DERR1-10.2196/20904